Completeness of the dataset (%) - stage complete by cancer site groups summary (persons)
Country average (population) | Country average (country) | England | Scotland | Wales1 | Northern Ireland | Republic of Ireland | |
---|---|---|---|---|---|---|---|
All invasive xnmsc | 80.6% | 78.6% | 81.9% | 67.5% | 79.7% | 85.3% | |
Haematology | 65.3% | 52.1% | 70.4% | 0.0% | 61.7% | 76.3% | |
Head and Neck | 89.1% | 88.6% | 90.5% | 74.5% | 91.4% | 97.9% | |
Lower GI | 88.6% | 87.0% | 89.8% | 74.6% | 91.9% | 91.6% | |
Upper GI | 82.7% | 79.6% | 83.9% | 72.8% | 86.8% | 74.9% | |
HPB | 73.1% | 73.2% | 73.5% | 72.2% | 63.6% | 83.3% | |
Bronchus & Lung | 93.1% | 92.5% | 93.5% | 89.8% | 93.5% | 93.2% | |
Melanoma of skin | 89.6% | 80.0% | 94.0% | 38.4% | 89.7% | 98.0% | |
Breast | 92.5% | 90.4% | 93.6% | 84.2% | 85.7% | 98.0% | |
Cervix | 92.1% | 95.6% | 91.2% | 95.7% | 97.1% | 98.5% | |
Other Female Genitals | 86.8% | 86.6% | 87.6% | 75.6% | 88.5% | 94.6% | |
Prostate | 90.0% | 89.5% | 90.3% | 83.9% | 92.2% | 91.7% | |
Bladder | 85.4% | 81.0% | 87.5% | 63.3% | 83.9% | 89.2% | |
Kidney | 85.2% | 83.5% | 86.2% | 77.1% | 77.7% | 93.0% | |
Thyroid and other endocrine glands | 76.9% | 81.0% | 76.3% | 75.1% | 75.4% | 97.1% | |
Other invasive cancer | 62.0% | 53.9% | 66.1% | 21.1% | 58.0% | 70.3% | |
Non-Melanoma Skin Cancer | 3.2% | 6.4% | 3.0% | 0.0% | 3.4% | 19.2% |